The first round of negotiations to renew the risk-sharing agreement (RSA) contract for the severe atopic dermatitis treatment ‘Dupixent (dupilumab, Sanofi)’ has fallen through.

The company and the National Health Insurance Service plan to discuss Dupixent’s RSA renewal through additional negotiations.

According to the industry on the 11th, the first round of negotiations for Dupixent's RSA renewal fell through. Dupixent was listed for reimbursement through the RSA in 2020. Three types of RSA - refund type for initial treatment, refund type, and expenditure cap type, were applied for reimbursement.

At the time, the Ministry of Health and Welfare explained, "The pharmace